Aliases & Classifications for Acute Mountain Sickness

Aliases & Descriptions for Acute Mountain Sickness:

Name: Acute Mountain Sickness 50 69
High Altitude Pulmonary Edema 50 56 69
High Altitude Cerebral Edema 50 69
Altitude Sickness 50 69
Mountain Sickness 50 69
Altitude Anoxia 50

Characteristics:

Orphanet epidemiological data:

56
high altitude pulmonary edema
Prevalence: 1-9/1000000 (Europe);

Classifications:



External Ids:

Orphanet 56 ORPHA330012
ICD10 via Orphanet 34 J81

Summaries for Acute Mountain Sickness

MalaCards based summary : Acute Mountain Sickness, also known as high altitude pulmonary edema, is related to chronic mountain sickness and unilateral absence of a pulmonary artery, and has symptoms including cheyne-stokes respiration, coughing and dyspnea. An important gene associated with Acute Mountain Sickness is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cellular Senescence and Development HGF signaling pathway. The drugs Ibuprofen and Acetazolamide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and brain, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 71 Altitude sickness—also known as acute mountain sickness (AMS), is a pathological effect of high... more...

Related Diseases for Acute Mountain Sickness

Diseases in the Acute Mountain Sickness family:

Chronic Mountain Sickness

Diseases related to Acute Mountain Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
id Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 11.1
2 unilateral absence of a pulmonary artery 11.0
3 hypoxia 10.5
4 cerebritis 10.5
5 colonic lymphangioma 10.3 ACE PIK3C2A
6 focal dystonia 10.3 ACE NOS3 VEGFA
7 microphthalmia, isolated, with coloboma 7 10.3 ACE MB PIK3C2A
8 proliferating trichilemmal cyst 10.3 EDN1 NOS3
9 endotheliitis 10.3
10 prostate neuroendocrine neoplasm 10.2 ACE AGTR1 MB
11 iris disease 10.2 ACE AGTR1 NOS3
12 eye degenerative disease 10.2 ACE AGTR1 NOS3
13 urinary bladder posterior wall cancer 10.2 HIF1A PIK3C2A VEGFA
14 joint disorders 10.2 ACE AGTR1 NOS3
15 ectodermal dysplasia 9, hair/nail type 10.2 EDN1 NOS3 VEGFA
16 vernal conjunctivitis 10.2 ACE FLT1 VEGFA
17 aphasia 10.2 ACE EDN1 NOS3
18 cerebral convexity meningioma 10.2 ACE AGTR1 NOS3
19 zellweger syndrome 10.2 EDN1 NOS3 VEGFA
20 capillary hemangioma 10.2 EDN1 NOS3 VEGFA
21 headache 10.2
22 viral hepatitis 10.2 ACE EDN1 NOS3
23 poikiloderma with neutropenia 10.2 ADRB2 EDN1 NOS3
24 isolated anterior cervical hypertrichosis 10.2 HIF1A VEGFA
25 limb ischemia 10.2 ACE EDN1 NOS3
26 intracranial cysts 10.2 NOS3 VEGFA
27 eastern equine encephalitis 10.2 ACE AGTR1 EDN1
28 petrositis 10.2 ACE AGTR1 EDN1
29 albinism, oculocutaneous, type ib 10.2 FLT1 HIF1A VEGFA
30 pyelonephritis 10.2 ACE EDN1 NOS3 PIK3C2A
31 diabetic encephalopathy 10.1 ACE EDN1 NOS3 S100B
32 adult t-cell leukemia 10.1 ACE EDN1 MB PIK3C2A
33 myelinoclastic diffuse sclerosis 10.1 ENO2 S100B
34 neuropathy with hearing impairment 10.1 FLT1 VEGFA VHL
35 lymphatic system disease 10.1 ENO2 VEGFA
36 cleft palate cardiac defect ectrodactyly 10.1 HIF1A VEGFA VHL
37 autoimmune-related retinopathy and optic neuropathy 10.1 ACE EDN1 NOS3 VEGFA
38 lymphadenitis 10.1 ACE AGTR1 EDN1 NOS3
39 alpha-2-plasmin inhibitor deficiency 10.1 ACE AGTR1 EDN1 NOS3
40 pulmonary edema 10.1
41 sarcomatoid renal cell carcinoma 10.1 HIF1A VEGFA VHL
42 fiedler's myocarditis 10.1 AGTR1 EDN1 NOS3 VEGFA
43 isolated plagiocephaly 10.1 ENO2 FLT1 VEGFA
44 maxillary neoplasm 10.1 ENO2 FLT1 VEGFA
45 obstructive jaundice 10.1 EDN1 FLT1 VEGFA
46 erythrocytosis, familial, 2 10.1 HIF1A VEGFA VHL
47 pericarditis 10.1 ACE EDN1 NOS3 VEGFA
48 citrullinemia, type ii, neonatal-onset 10.1 ACE AGTR1 FLT1 NOS3 VEGFA
49 oppositional defiant disorder 10.1 ACE EDN1 HIF1A NOS3 VEGFA
50 benign schwannoma 10.1 ENO2 S100B

Graphical network of the top 20 diseases related to Acute Mountain Sickness:



Diseases related to Acute Mountain Sickness

Symptoms & Phenotypes for Acute Mountain Sickness

UMLS symptoms related to Acute Mountain Sickness:


cheyne-stokes respiration, coughing, dyspnea, hoarseness

MGI Mouse Phenotypes related to Acute Mountain Sickness:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 VEGFA VHL ACE ADRB2 AGTR1 BDKRB2
2 behavior/neurological MP:0005386 10.36 CCK ENO2 FLT1 HIF1A HIF1AN NOS3
3 cellular MP:0005384 10.34 ADRB2 BDKRB2 EGLN1 ENO2 FLT1 HIF1A
4 homeostasis/metabolism MP:0005376 10.34 ACE ADRB2 AGTR1 BDKRB2 CCK EDN1
5 growth/size/body region MP:0005378 10.32 FLT1 HIF1A HIF1AN MB NOS3 PIK3C2A
6 hematopoietic system MP:0005397 10.23 HIF1A MB NOS3 PIK3C2A VEGFA VHL
7 endocrine/exocrine gland MP:0005379 10.15 ACE ADRB2 BDKRB2 CCK EDN1 HIF1A
8 immune system MP:0005387 10.14 NOS3 PIK3C2A VEGFA VHL ACE ADRB2
9 embryo MP:0005380 10.11 EDN1 EGLN1 FLT1 HIF1A MB PIK3C2A
10 adipose tissue MP:0005375 10.1 ACE ADRB2 AGTR1 BDKRB2 HIF1AN NOS3
11 muscle MP:0005369 10.02 ADRB2 EDN1 EGLN1 FLT1 HIF1A HIF1AN
12 nervous system MP:0003631 10 ADRB2 AGTR1 CCK EDN1 EGLN1 ENO2
13 liver/biliary system MP:0005370 9.91 NOS3 VEGFA VHL ACE EGLN1 HIF1A
14 normal MP:0002873 9.81 BDKRB2 EDN1 FLT1 HIF1A HIF1AN NOS3
15 renal/urinary system MP:0005367 9.65 ACE AGTR1 BDKRB2 EDN1 EGLN1 HIF1A
16 respiratory system MP:0005388 9.17 EGLN1 ENO2 HIF1A HIF1AN MB NOS3

Drugs & Therapeutics for Acute Mountain Sickness

Drugs for Acute Mountain Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672
2
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-66-5 1986
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Nifedipine Approved Phase 4 21829-25-4 4485
6
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
7
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
8
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
9
Metformin Approved Phase 4 657-24-9 14219 4091
10 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
11 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antioxidants Phase 4,Phase 3,Phase 1,Phase 2
19
Angiotensin II Phase 4 68521-88-0, 11128-99-7 65143 172198
20 Sildenafil Citrate Phase 4 171599-83-0
21 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
22 Epoetin alfa Phase 4 113427-24-0
23 calcium channel blockers Phase 4
24 diuretics Phase 4,Phase 3,Phase 1,Phase 2
25 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
26
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1
27 Chelating Agents Phase 4
28 N-monoacetylcystine Phase 4,Phase 1,Phase 2
29 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
31 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
32 Hematinics Phase 4,Phase 2,Phase 3
33 Tocolytic Agents Phase 4,Phase 1
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 3,Phase 1
36 Hormones Phase 4,Phase 3,Phase 2,Phase 1
37 Performance-Enhancing Substances Phase 4
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
39 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Angiotensin II Type 1 Receptor Blockers Phase 4
41 Angiotensin Receptor Antagonists Phase 4
42 Angiotensinogen Phase 4
43 Phosphodiesterase 5 Inhibitors Phase 4,Phase 1,Phase 2
44 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
45 Expectorants Phase 4,Phase 1,Phase 2
46 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Anticoagulants Phase 4
48 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
49 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
50 Antihypertensive Agents Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 126)
id Name Status NCT ID Phase
1 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4
2 A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Completed NCT01418157 Phase 4
3 Ibuprofen vs Acetaminophen for AMS Prevention Completed NCT02244437 Phase 4
4 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4
5 Altitude Related Illness In Patients With Respiratory Disease Completed NCT02450968 Phase 4
6 Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Completed NCT00627965 Phase 4
7 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4
8 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4
9 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4
10 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4
11 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4
12 HIGH Altitude CArdiovascular REsearch in the ANDES Completed NCT01830530 Phase 4
13 Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude Recruiting NCT03177811 Phase 4
14 Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease Recruiting NCT03156231 Phase 4
15 Three New Ideas to Protect Special Forces From the Stress of High Altitude Active, not recruiting NCT02463357 Phase 4
16 Induced Changes in Ventilatory Responsiveness and Altitude Exposure Terminated NCT01241513 Phase 4
17 Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Completed NCT00664001 Phase 3
18 Altitude Sickness Prevention and Efficacy of Comparative Treatments Completed NCT02604173 Phase 3
19 Drug Combination on Exercise Performance at High Altitude Completed NCT01902758 Phase 2, Phase 3
20 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Completed NCT01171794 Phase 3
21 American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL Completed NCT00752895 Phase 3
22 Phase 2/3 Study of IGSC, 20% in PIDD Completed NCT01218438 Phase 2, Phase 3
23 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00720109 Phase 2, Phase 3
24 Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3
25 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3
26 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
27 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
28 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3
29 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3
30 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Recruiting NCT02101853 Phase 3
31 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT01371981 Phase 3
32 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Recruiting NCT02112916 Phase 3
33 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Recruiting NCT02883049 Phase 3
34 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Recruiting NCT01190930 Phase 3
35 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting NCT00557193 Phase 3
36 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting NCT00103285 Phase 3
37 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3
38 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3
39 Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia Active, not recruiting NCT01595048 Phase 2, Phase 3
40 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Active, not recruiting NCT00354835 Phase 3
41 Inhaled Budesonide for Altitude Illness Prevention Withdrawn NCT02941510 Phase 3
42 NSAID RCT for Prevention of Altitude Sickness Unknown status NCT01606527 Phase 2
43 Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Unknown status NCT01682551 Phase 2
44 Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Completed NCT01536288 Phase 2
45 Prevention of High Altitude Pulmonary Edema Completed NCT00274430 Phase 1, Phase 2
46 Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Completed NCT01187108 Phase 1, Phase 2
47 Rapid Acclimatization to Hypoxia at Altitude Completed NCT01702025 Phase 1, Phase 2
48 Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance Completed NCT01871142 Phase 1, Phase 2
49 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00873093 Phase 2
50 Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Completed NCT00006462 Phase 2

Search NIH Clinical Center for Acute Mountain Sickness

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Acute Mountain Sickness

Anatomical Context for Acute Mountain Sickness

MalaCards organs/tissues related to Acute Mountain Sickness:

39
Endothelial, Heart, Brain, Lung, Testes, Pituitary, Neutrophil

Publications for Acute Mountain Sickness

Articles related to Acute Mountain Sickness:

(show top 50) (show all 563)
id Title Authors Year
1
Is acute mountain sickness related to trait anxiety? A normobaric chamber study. ( 28069461 )
2017
2
In Response to Risk Determinants of Acute Mountain Sickness by Lawrence and Reid. ( 27939594 )
2016
3
Acute Mountain Sickness Symptoms Depend on Normobaric versus Hypobaric Hypoxia. ( 27847819 )
2016
4
Vascular Endothelial Function Assessed by Postischemic Diastolic Blood Pressure Is Associated with Acclimatization and Acute Mountain Sickness. ( 26977539 )
2016
5
Subjective assessment of acute mountain sickness: investigating the relationship between the Lake Louise Self-Report, a visual analogue scale and psychological well-being scales. ( 27722064 )
2016
6
Acute Mountain Sickness Symptom Severity at the South Pole: The Influence of Self-Selected Prophylaxis with Acetazolamide. ( 26848757 )
2016
7
Acute mountain sickness and duration of pre-exposure to high altitude. ( 27483198 )
2016
8
Relation of Activity Patterns and Biochemical Factors to Acute Mountain Sickness in the South Pole: 2056 Board #208 June 2, 3: 30 PM - 5: 00 PM. ( 27360881 )
2016
9
Differences Between the "Chinese AMS Score" and the Lake Louise Score in the Diagnosis of Acute Mountain Sickness. ( 27227918 )
2016
10
Evidence for cerebral edema, cerebral perfusion, and intracranial pressure elevations in acute mountain sickness. ( 27099800 )
2016
11
Inevitable Acclimatization and Acute Mountain Sickness. ( 26972140 )
2016
12
Novel drugs in the management of acute mountain sickness and high altitude pulmonary edema. ( 26766920 )
2016
13
Acute mountain sickness and oxygen saturation. ( 26922356 )
2016
14
Letter to the Editor re: Use of Statins for Prophylaxis Against Acute Mountain Sickness: Letter. ( 26802383 )
2016
15
Prevalence of acute mountain sickness on Mount Fuji: A pilot study. ( 27147731 )
2016
16
Acute Mountain Sickness (AMS) Knowledge Among High Altitude Marathon Runners Competing in the Everest Marathon. ( 26712333 )
2016
17
Acute mountain sickness among tourists visiting the high-altitude city of Lhasa at 3658A m above sea level: a cross-sectional study. ( 27252854 )
2016
18
Letter to the Editor re: Use of Statins for Prophylaxis Against Acute Mountain Sickness: Response. ( 26802382 )
2016
19
Endothelin-1 Plasma Levels and Acute Mountain Sickness. ( 27058016 )
2016
20
Incidence and risk factors associated with acute mountain sickness in children trekking on Jade Mountain, Taiwan. ( 26782126 )
2016
21
Risk Determinants of Acute Mountain Sickness and Summit Success on a 6-Day Ascent of Mount Kilimanjaro (5895 m). ( 26948557 )
2016
22
Acute mountain sickness in children at Jade Mountain. ( 27178162 )
2016
23
Optic Nerve Sheath Diameter and Acute Mountain Sickness. ( 26795046 )
2016
24
Association of Cognitive Performance with Time at Altitude, Sleep Quality, and Acute Mountain Sickness Symptoms. ( 27460198 )
2016
25
Acute mountain sickness and arterial oxygen saturation. ( 26922357 )
2016
26
High Altitude and Acute Mountain Sickness and Changes in Circulating Endothelin-1, Interleukin-6, and Interleukin-17a. ( 26680502 )
2016
27
Analysis of High-altitude Syndrome and the Underlying Gene Polymorphisms Associated with Acute Mountain Sickness after a Rapid Ascent to High-altitude. ( 27982053 )
2016
28
Association between smoking and the risk of acute mountain sickness: a meta-analysis of observational studies. ( 27980800 )
2016
29
A higher baseline somatization score at sea level as an independent predictor of acute mountain sickness. ( 27640135 )
2016
30
Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level. ( 27433337 )
2016
31
Acute Mountain Sickness and Vascular Endothelial Dysfunction. ( 27295418 )
2016
32
Effects of dietary nitrate supplementation on symptoms of acute mountain sickness and basic physiological responses in a group of male adolescents during ascent to Mount Everest Base Camp. ( 27593617 )
2016
33
Is Smoking a Predictor for Acute Mountain Sickness? Findings From a Meta-Analysis. ( 26419295 )
2015
34
Statin use and the development of acute mountain sickness. ( 25946733 )
2015
35
Field Ultrasound Evaluation of Central Volume Status and Acute Mountain Sickness. ( 25864086 )
2015
36
Hypoxia, Hypobaria, and Exercise Duration Affect Acute Mountain Sickness. ( 26102141 )
2015
37
In search for better pharmacological prophylaxis for acute mountain sickness: looking in other directions. ( 25753758 )
2015
38
Remote ischemic preconditioning delays the onset of acute mountain sickness in normobaric hypoxia. ( 25742960 )
2015
39
Effect of Personality Traits on Development of Acute Mountain Sickness in Rapid Entry Population. ( 27398778 )
2015
40
Sleep disordered breathing and acute mountain sickness in workers rapidly transported to the South Pole (2835m). ( 25655218 )
2015
41
Does Cerebral Water and Ion Imbalance After Intense Exercise of Short Duration Under Hypoxic Conditions Contribute to Occurrence of Acute Mountain Sickness? ( 26057721 )
2015
42
Role of remote ischemic preconditioning against acute mountain sickness during early phase. ( 26265758 )
2015
43
Smoking Increases the Risk of Acute Mountain Sickness. ( 25747540 )
2015
44
Optic Nerve Sheath Diameter Increase on Ascent to High Altitude: Correlation With Acute Mountain Sickness. ( 26269295 )
2015
45
Pharmacology of Acute Mountain Sickness: Old Drugs and Newer Thinking. ( 26294748 )
2015
46
A specific objective supplemental factor in evaluating acute mountain sickness: I9HR in combination with SaO2. ( 26504587 )
2015
47
Obesity is a risk factor for acute mountain sickness: a prospective study in Tibet railway construction workers on Tibetan plateau. ( 25635984 )
2015
48
The Relationship Between Baseline Exhaled Nitric Oxide Levels and Acute Mountain Sickness. ( 25782333 )
2015
49
Genetic variants of endothelial PAS domain protein 1 are associated with susceptibility to acute mountain sickness in individuals unaccustomed to high altitude: A nested case-control study. ( 26622413 )
2015
50
Impact of Study Design on Reported Incidences of Acute Mountain Sickness: A Systematic Review. ( 26230550 )
2015

Variations for Acute Mountain Sickness

Expression for Acute Mountain Sickness

Search GEO for disease gene expression data for Acute Mountain Sickness.

Pathways for Acute Mountain Sickness

Pathways related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 25)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B VEGFA
2
Show member pathways
12.71 EGLN1 HIF1A NOS3 VEGFA VHL
3
Show member pathways
12.71 BDKRB2 EDN1 HSPA1A HSPA1B NOS3 VEGFA
4 12.58 AGTR1 BDKRB2 EGLN1 HIF1A VEGFA VHL
5 12.34 ADRB2 FLT1 HSPA1A HSPA1B
6
Show member pathways
12.27 CCK FLT1 NOS3 VEGFA
7
Show member pathways
12.15 ADRB2 AGTR1 BDKRB2 NOS3
8
Show member pathways
12.12 FLT1 NOS3 PIK3C2A VEGFA
9 11.82 AGTR1 EDN1 NOS3 VEGFA
10
Show member pathways
11.77 FLT1 HIF1A NOS3 VEGFA VHL
11
Show member pathways
11.71 FLT1 NOS3 PIK3C2A
12 11.71 EGLN1 FLT1 HIF1A HIF1AN NOS3
13
Show member pathways
11.7 ACE AGTR1 BDKRB2 NOS3
14 11.59 ACE ADRB2 AGTR1
15 11.57 EDN1 EGLN1 HIF1A VEGFA
16 11.55 EDN1 EGLN1 ENO2 FLT1 HIF1A NOS3
17
Show member pathways
11.53 HSPA1A HSPA1B NOS3
18 11.22 EDN1 EGLN1 HIF1A HIF1AN VEGFA
19
Show member pathways
11.19 EDN1 HIF1A VEGFA
20 11.09 EGLN1 FLT1 HIF1AN VEGFA VHL
21 11.01 EDN1 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B
22 11 FLT1 HIF1A NOS3 VEGFA
23 10.83 HIF1A HIF1AN VHL
24 10.56 HIF1A HIF1AN VEGFA
25 10.5 MB NOS3

GO Terms for Acute Mountain Sickness

Cellular components related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 ACE EDN1 EGLN1 ENO2 FLT1 HIF1A

Biological processes related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.92 FLT1 HIF1A NOS3 VEGFA
2 regulation of blood pressure GO:0008217 9.79 ACE EDN1 NOS3
3 positive regulation of MAP kinase activity GO:0043406 9.77 EDN1 FLT1 VEGFA
4 positive regulation of angiogenesis GO:0045766 9.76 FLT1 HIF1A NOS3 VEGFA
5 response to hypoxia GO:0001666 9.72 EDN1 EGLN1 HIF1A MB VEGFA
6 cellular response to hypoxia GO:0071456 9.71 EDN1 HIF1A S100B VEGFA
7 protein refolding GO:0042026 9.64 HSPA1A HSPA1B
8 regulation of cell death GO:0010941 9.63 HSPA1A HSPA1B
9 negative regulation of inclusion body assembly GO:0090084 9.62 HSPA1A HSPA1B
10 regulation of blood vessel diameter GO:0097746 9.61 ACE AGTR1
11 blood vessel morphogenesis GO:0048514 9.61 EDN1 FLT1 HIF1A
12 positive regulation of receptor biosynthetic process GO:0010870 9.59 EDN1 HIF1A
13 oxygen homeostasis GO:0032364 9.58 EGLN1 HIF1A
14 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.58 EDN1 NOS3
15 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.57 ACE AGTR1
16 positive regulation of tumor necrosis factor-mediated signaling pathway GO:1903265 9.56 HSPA1A HSPA1B
17 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.55 ACE VEGFA
18 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 HIF1A VEGFA
19 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.52 HIF1AN VHL
20 positive regulation of microtubule nucleation GO:0090063 9.51 HSPA1A HSPA1B
21 cellular heat acclimation GO:0070370 9.49 HSPA1A HSPA1B
22 positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070434 9.48 HSPA1A HSPA1B
23 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.43 FLT1 HIF1A VEGFA
24 positive regulation of chemokine-mediated signaling pathway GO:0070101 9.37 EDN1 HIF1A
25 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.35 EGLN1 HIF1A HIF1AN VEGFA VHL
26 regulation of vasodilation GO:0042312 9.33 ACE ADRB2 AGTR1
27 regulation of vasoconstriction GO:0019229 8.92 ACE AGTR1 BDKRB2 EDN1
28 negative regulation of apoptotic process GO:0043066 10.04 HIF1A HSPA1A HSPA1B VEGFA VHL
29 positive regulation of cell proliferation GO:0008284 10.03 CCK EDN1 FLT1 S100B VEGFA

Molecular functions related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled GO:0042623 9.26 HSPA1A HSPA1B
2 C3HC4-type RING finger domain binding GO:0055131 9.16 HSPA1A HSPA1B
3 enzyme binding GO:0019899 9.1 ADRB2 EGLN1 HIF1A HSPA1A HSPA1B VHL
4 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1

Sources for Acute Mountain Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....